•There is currently not a lot of research on the nickel-based 3,5-Disubstituted ∆2-isoxazoline. It is predictable that more research will be done on this nickel-based isoxazoline in the future due to its promise. However, if the nickel proves to be inadequate at cyclizing to form the isoxazole ring research regarding it will be discontinued. •There will probably be much more research done on the palladium-based cyclization because of its proven success rate. •More experiments will also be performed with many more derivatives and reactants to find out the most effective way to produce 3,5-Disubstituted ∆2-isoxazolines, as well as which derivatives work the best to inhibit MIF and shield ß-cells in the pancreas. •All of this research will be geared towards synthesizing 3,5-Disubstituted ∆2-isoxazolines as effective MIF inhibitors that can treat diabetes and cancer.